Mesoblast (MESO) completes patient treatment in pivotal Phase 3
Mesoblast (MESO) says it has achieved a major milestone by completing patient treatment in its pivotal Phase 3 trial for chronic low back pain.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.